
Press Release

GlycoVaxyn Winner of the Life Sciences Prize 2006

Last night the Swiss Life Sciences Prize was awarded the third time in Basel in the framework of the Life Sciences Week.

Basel, October 19, 2006. The Swiss Life Sciences Prize 2006 was awarded to the company GlycoVaxyn AG, based in Wädenswil. The prize of CHF 10'000, awarded yesterday evening for the third time, stands under the patronage of the Swiss Biotech Association and BioValley Basel, and is intended for young Swiss companies in the Pharma and Medtech sectors. Sponsors of the Swiss Life Sciences Prize are BioMedinvest, Novartis Venture Fund, Varuma and Venture Incubator.

GlycoVaxyn, a spin-off company of the ETH Zürich, is developing novel conjugated vaccines based on an innovative manufacturing approach. Over the last 20 years, such highly efficient vaccines have provided safe immunizations in humans. Their manufacturing involves a complex and costly chemical conjugation step, which is circumvented by GlycoVaxyn's technology, where recombinant *Escherichia coli* bacteria link antigenic sugar chains, which originate from the cell surface of pathogenic bacteria, in vivo to carrier proteins. This biotechnological process will be developed to the point where novel conjugated vaccines offer dependable protection at an affordable prize. GlycoVaxyn is managed by the two founders Michael Wacker and Urs Tuor.

The Life Sciences Prize 2006 wants to emphasize the importance of young Life Sciences companies. The award winning company is a good example how to use the enormous scientific potential in Switzerland.

Press Releases and picture are available at www.lifesciencesprize.ch and www.glycovaxyn.com

Contact Person Jury: Dr. Matthias Staehelin, VISCHER Attorneys at law, Tel. 061 279 33 53 / 079 435 73 54, e-mail: mstaehelin@vischer.com

Contact Person GlycoVaxyn: Urs Tuor, Founder and Chairman of the Board of Directors of GlycoVaxyn AG, Tel: +41 44 680 13 31, Fax: +41 44 680 13 32, e-mail: urs.tuor@glycovaxyn.com

Life Sciences Prize Jury Members:

Dr. Bruno Dalle Carbonare, Head Tech transfer office, University of Basel
Dr. Reinhard Glück, President Swiss Biotech Association and Etna Biotech
Dr. Paul Hadvary, Arpida AG
Dr. Franz Saladin, Head Life Sciences, Basel Chamber of Commerce
Dr. Thomas Schreier, Head Research Pentapharm und Board member BioValley Basel
Dr. Matthias Staehelin, Head Life Sciences VISCHER
Dr. Henri Zinsli, Chairman COVALYS Biosciences Ltd
Jürg Zürcher, Head Life Sciences Ernst & Young